2-丁基二硫基-1H-咪唑 | 141400-57-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 中文名称: 2-丁基二硫基-1H-咪唑
• 中文别名: 3-噁丁烷醇,2,2,4-三甲基-3-(1-甲基乙基)-,反-(9CI)
• 英文名称: n-butyl 2-mercaptoimidazolyl disulfide
• 英文别名: n-butyl 2-imidazolyl disulfide；2-(butyldisulfanyl)-1H-imidazole
• CAS: 141400-57-9
• 化学式: C₇H₁₂N₂S₂
• 分子量: 188.318
• InChiKey: SBXVGBRRYUGRRZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  11
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.57
• 拓扑面积：
  79.3
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  2-n-butylmercaptoisothiourea hydrochloride 、 2-巯基咪唑 在 碳酸氢钠 作用下， 以 甲醇 、 水 为溶剂， 反应 1.0h， 以82%的产率得到2-丁基二硫基-1H-咪唑
  参考文献：
  名称：

  Synthesis and evaluation of imidazolyl disulfides for selective cytotoxicity to hypoxic EMT6 tumor cells in vitro

  摘要：

  Two series of disulfides were synthesized and evaluated in vitro for selective hypoxic tumor cell cytotoxicity using EMT6 cells. While the series of alkyl 5-nitrobenzimidazolyl disulfides displayed no selectivity, two alkyl imidazolyl disulfides, devoid of a nitro function, showed preferential toxicity to EMT6 cells treated under hypoxic conditions. Select agents of the alkyl imidazolyl series were found to deplete cellular glutathione (GSH) while the corresponding alkyl nitrobenzimidazolyl derivatives did not. One disulfide displaying selective hypoxic cell toxicity, n-butyl 2-imidazolyl disulfide, 10, caused significantly greater depletion of GSH under aerobic conditions. Removal of cellular GSH with buthionine sulfoximine (BSO) prior to exposure to 10 caused an increase in its toxicity and a loss of any differential between aerobic and hypoxic conditions. It is speculated that the diminished aerobic vs hypoxic toxicity of the agent toward EMT6 cells is due to a greater ability of 10 to interact with GSH under aerobic conditions as reflected by the greater GSH depletion.

  DOI：

  10.1016/0223-5234(92)90057-8

文献信息

• Asymmetric disulfides and methods of using same
  申请人：——

  公开号：US20030176512A1

  公开（公告）日：2003-09-18

  The present invention is directed to a composition or formulation which includes an asymmetric disulfide which alone or in combination inhibits or interferes with cellular redox function, as well as a method of using same to restore normal cellular function. More specifically, the composition of the present invention interacts with, interferes with or inhibits abnormal cellular proliferation and restores or prevents inhibition of cellular apoptosis.

  本发明涉及一种包含不对称二硫化物的组合物或制剂，该组合物或制剂可单独或联合抑制或干扰细胞氧化还原功能，本发明还涉及使用该组合物或制剂恢复正常细胞功能的方法。更具体地说，本发明的组合物与细胞异常增殖相互作用，干扰或抑制细胞异常增殖，恢复或防止抑制细胞凋亡。
• Method of preselection patients for anti-VEGF, anti-HIF-1 or anti-thioredoxin therapy
  申请人：Powis Garth

  公开号：US20060104902A1

  公开（公告）日：2006-05-18

  The present invention generally relates to methods of preselecting patients for treatment with an anti-VEGF therapy, anti-HIF-1 therapy or anti-thioredoxin therapy. Aspects of the invention combine methods of dynamic contrast enhanced-MRI and diffusion weighted-MRI for the detection of tumor histology. The methodology disclosed herein detects tissue blood volume, tumor vascularity, and abnormal capillary permeability, thereby determining tumor vascularity to determine whether a patient should be administered such therapy.

  本发明一般涉及预选患者接受抗血管内皮生长因子疗法、抗 HIF-1 疗法或抗硫氧还蛋白疗法治疗的方法。本发明的各个方面结合了动态对比增强-MRI 和扩散加权-MRI 方法，用于检测肿瘤组织学。本发明公开的方法可检测组织血容量、肿瘤血管性和异常毛细血管通透性，从而确定肿瘤血管性，以确定患者是否应接受此类治疗。
• METHOD OF PRESELECTION PATIENTS FOR ANTI-VEGF, ANTI-HIF-1 OR ANTI-THIOREDOXIN THERAPY
  申请人：Prolx Pharmaceuticals Corp.

  公开号：EP1786477A2

  公开（公告）日：2007-05-23
• METHODS OF PATIENT SELECTION AND TREATING TRXR- OR PRDX-OVEREXPRESSED CANCERS
  申请人：Triact Therapeutics, Inc.

  公开号：EP3654958A1

  公开（公告）日：2020-05-27
• Asymmetric Disulfides and methods of using same
  申请人：——

  公开号：US20040116496A1

  公开（公告）日：2004-06-17

  The present invention is directed to a composition or formulation which includes an asymmetric disulfide which alone or in combination inhibits or interferes with cellular redox function, as well as a method of using same to restore normal cellular function. More specifically, the composition of the present invention are delivered to the patient over a period of time and interact with, interfere with, or inhibit abnormal cellular proliferation and restores or prevents inhibition of cellular apoptosis.